Crohn's Disease Newswire (Page 3)

Comprehensive Real-Time News Feed for Crohn's Disease. (Page 3)

Results 41 - 60 of 3,115 in Crohn's Disease

  1. Neovacs Announces Top Line Phase IIb Clinical Trial Results of...Read the original story w/Photo

    Yesterday | GlobeNewswire

    ... id is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas

    Comment?

  2. Galapagos regains full rights to GPR84 inhibitor GLPG1205Read the original story w/Photo

    Yesterday | AndhraNews

    ... arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease.Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in ...

    Comment?

  3. Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board.Read the original story

    Monday | Sys-Con Media

    ... product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic ...

    Comment?

  4. Adults in England living with Ulcerated Colitis (UC) will have...Read the original story w/Photo

    Monday | Medical News Today

    ... of patients worldwide living with auto-immune conditions such as rheumatoid arthritis , psoriasis , Crohn's Disease as well as Ulcerative Colitis. Adalimumab is supported by extensive efficacy, safety and real world evidence which has accumulated ...

    Comment?

  5. UK Patients With Moderately to Severely Active Ulcerative Colitis...Read the original story

    Sunday | Sys-Con Media

    The National Institute for Health and Care Excellence has issued its Final Appraisal Document recommending REMICADE A , HUMIRA A and SIMPONI A , within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.[1] SIMPONI is recommended only if MSD provides the 100mg dose at the same cost as the 50mg dose, as agreed in the patient access scheme.

    Comment?

  6. Avera McKennan: Controlling Crohn's Diease and ColitisRead the original story w/Photo

    Sunday | KSFY

    ... Sidel. She thought it was appendicitis but an ER trip finally revealed a cause to Kristi's pain. She had Crohn's Disease. "I had no idea and then when they start to explain it to you and you are slightly embarrassed because it's something you don't ...

    Comment?

  7. On The MoveRead the original story w/Photo

    Saturday Dec 13 | Albany Times Union

    ... at Albany Medical College. Seril specializes in inflammatory bowel disease, including ulcerative colitis and Crohn's disease, and inflammation of the entire gastrointestinal tract. Micheal Tadros , an expert in complex esophageal diseases, was ...

    Comment?

  8. New Perfect Holiday Gifts For Loved Ones Suffering from Flatulence, Celiac Disease, Diabetes & MoreRead the original story

    Friday Dec 12 | PR Log

    ... flatulence odor. Due to overwhelming health conditions like Celiac Disease, Irritable Bowel Syndrome, Crohn's Disease, Diabetes, lactose intolerance, Trimethylaminuria or TMAU and man more...flatulence or farting is now more common than ever. Having ...

    Comment?

  9. Stick out your tongue: Tongue appearance and illnessRead the original story w/Photo

    Friday Dec 5 | Science Daily

    ... use. Longitudinal furrows on the tongue are associated with syphilis. Ulcers may indicate the presence of Crohn's disease or colitis and various other conditions. The team's automated diagnostic, however, utilizes the condition of the tongue in ...

    Comment?

  10. Why Michael Burns isn't your ordinary Dallas Marathon runnerRead the original story w/Photo

    Friday Dec 12 | Dallas Morning News

    Runner Michael Burns grimaces during therapy with his chiropractor Dr. Lezlie Maloy at Spring Valley Spine and SportsCare in Dallas on Dec. 4, 2014. Burns is planning to run the MetroPCS Dallas Marathon despite having cerebral palsy and Crohn's Disease.

    Comment?

  11. Lebanon Breakfast Rotary Club presents donationRead the original story w/Photo

    Tuesday Dec 9 | Lebanon Democrat

    Lebanon Breakfast Rotary Club presents a donation to the Crohn's and Colitis Association. Pictured (from left) are Hal Bone, Kate Bone and Steve Shirley.

    Comment?

  12. Helmsley Trust gives another $11.3 million to Israeli causesRead the original story

    Friday Dec 12 | United Jewish Federation of Tidewater

    ... factors the contribute to the development of pouchitis, a form of inflammatory bowel disease associated with Crohn's Disease. Another $3.4 million grant will help to establish an Ambulatory Wing of the Organ Transplantation Center at Rabin Medical ...

    Comment?

  13. AXIM Biotechnologies Adds World Leaders In Cannabis Research And...Read the original story

    Thursday Dec 11 | BioSpace

    ... and novel drug delivery systems for Inflammatory Bowel Disease (IBD)/Irritable Bowel Syndrome (IBS) and Crohn's disease. Changoer continues, "It is our pleasure to announce that the world's most-renowned expert on medical cannabis, Dr. Arno ...

    Comment?

  14. Galapagos NV Selects Second Component Of Its Investigational Cystic Fibrosis Combination TreatmentRead the original story

    Thursday Dec 11 | BioSpace

    ... arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). ...

    Comment?

  15. Amgen And AstraZeneca PLC To Present Results From Phase 3 AMAGINE-1...Read the original story

    Thursday Dec 11 | BioSpace

    ... leads clinical development and commercialization for MEDI7183/AMG 181 (Phase 2 for ulcerative colitis and Crohn's disease), MEDI2070/AMG 139 (Phase 2 for Crohn's disease) and MEDI9929/AMG 157 (Phase 2 for asthma). About Amgen Amgen is committed to ...

    Comment?

  16. Mineralocorticoid and SGK1-Sensitive Inflammation and Tissue Fibrosis.Read the original story

    Thursday Dec 11 | CiteULike

    ... nephrotic syndrome, obstructive nephropathy, liver cirrhosis, fibrosing pancreatitis, peritoneal fibrosis, Crohn's disease and celiac disease. The untoward inflammatory and fibrosing effects of mineralocorticoids could be blunted or even reversed by ...

    Comment?

  17. Galapagos selects second component of its investigational cystic fibrosis combination treatmentRead the original story

    Thursday Dec 11 | PR-inside.com

    ... arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). ...

    Comment?

  18. Detection of intestinal damage in Crohn's diseaseRead the original story

    Thursday Dec 11 | GastroHep.com

    The latest issue of the Alimentary Pharmacology & Therapeutics identify magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease. In the treatment of Crohn's disease, mucosal healing has become a major goal, with the hope of avoiding intestinal damage from chronic inflammation.

    Comment?

  19. Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1(TM)...Read the original story

    Thursday Dec 11 | Freshnews

    ... leads clinical development and commercialization for MEDI7183/AMG 181 (Phase 2 for ulcerative colitis and Crohn's disease), MEDI2070/AMG 139 (Phase 2 for Crohn's disease) and MEDI9929/AMG 157 (Phase 2 for asthma). About Amgen Amgen is committed to ...

    Comment?

  20. AstraZeneca and Amgen to present detailed results from Phase III...Read the original story

    Thursday Dec 11 | PressReleasePoint

    ... leads clinical development and commercialisation for MEDI7183/AMG 181 (Phase II for ulcerative colitis and Crohn's disease), MEDI2070/AMG 139 (Phase II for Crohn's disease) and MEDI9929/AMG 157 (Phase II for asthma). Amgen is committed to unlocking ...

    Comment?